INTRODUCTION
One major mechanism that underlies the escape of tumors from immunological surveillance is a deficiency in the way tumor-specific T cells are optimally activated within the local microenvironment of lymphoid organs (1, 2) . For an effective T-cell response, signals from costimulatory receptors are required in addition to T-cell receptormediated recognition of antigen in the form of peptide-MHC expressed by antigen-presenting cells (APCs; Refs. 3 and 4). OX40 (also referred to as CD134) is a member of such costimulatory receptors and has a unique pattern of expression, which is, for the most part, restricted to CD4 ϩ T cells and is induced by T-cell receptor engagement by peptide antigen in the context of MHC class II (5) (6) (7) (8) . The ligand for OX40 (OX40L; also referred to as gp34) is a M r 34,000 type II membrane protein expressed on professional APCs such as dendritic cells, B cells, and macrophages (9 -11) . The interaction of OX40 with OX40L provides antigen-specific CD4 ϩ T cells with costimulatory signals that drive them to proliferate, augment effector functions such as cytokine secretions, and increase cell survival through inhibition of activation-induced cell death (7, (11) (12) (13) (14) (15) (16) (17) (18) .
Based on our understanding of the OX40L-OX40 function in immune responses, we hypothesized that in vivo genetic modification of tumor cells to express OX40L would trigger OX40 on tumor-responding CD4
ϩ T cells to develop effective antitumor immunity, thus suppressing the growth of the tumor. To test this hypothesis, we have constructed an E1 Ϫ recombinant adenovirus vector expressing OX40L (AdOX40L) to transfer the OX40L gene to tumor cells in vivo. The data demonstrate that in vivo OX40L-transduced tumor cells will elicit tumor-specific T helper 1 (Th1) immune responses and subsequently generate antitumor immunity mediated by cytotoxic T lymphocytes (CTLs) in the treated host, leading to inhibition of the tumor growth.
MATERIALS AND METHODS
Mice. Female C57Bl/6 (H-2 b ) and BALB/c (H-2 d ) mice, 6 -8 weeks of age, were purchased from Japan Charles River (Atsugi, Japan). Female CD4 ϩ T cell-deficient (B6.129S2-Cd4 tm1Mak ; Ref. 19 ) and CD8 ϩ T cell-deficient (B6.129S2-Cd8a tm1Mak ; Ref. 20) mice that had been backcrossed to the C57Bl/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME). Animals were housed under specific pathogen-free conditions in accordance with the guidelines of the institutional Animal Care and Use Committee.
Cell Lines. B16-F10 melanoma (B16; H-2 b ), Lewis lung carcinoma (LLC; H-2 b ), Colon-26 colon adenocarcinoma (H-2 d ), and BALB/3T3 fibroblast (H-2 d ) cell lines were obtained from the Cell Resource Center for Biomedical Research (Tohoku University, Sendai, Japan). E.G7-OVA, the mouse lymphoma cell line EL-4 (H-2 b ) modified to express chicken ovalbumin (OVA), was obtained from the American Type Culture Collection (Manassas, VA). B16, Colon-26, and BALB/3T3 cells were cultured in RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin. E.G7-OVA cells were grown in complete RPMI 1640 containing 0.4 mg/ml G418 (Invitrogen, Carlsbad, CA). Dendritic cells were generated from mouse bone marrow precursors as described previously (21) (22) (23) . LLC cells were maintained in complete DMEM (Sigma).
Adenovirus Vectors. AdOX40L and AdNull are replication-deficient serotype 5-based adenovirus vectors with E1 and E3 deletions in which the mouse OX40L cDNA (11) and no transgene, respectively, are under transcriptional control of the cytomegalovirus immediate-early enhancer and promoter. The recombinant viruses were amplified, purified using cesium chloride gradient ultracentrifugation, and titered as described previously (23) (24) (25) . All vectors were free of replication competent adenovirus.
Reverse Transcription-PCR. To confirm the expression of OX40L mRNA mediated by AdOX40L, total cellular RNA was extracted using ISO-GEN (Nippon Gene, Tokyo, Japan) from the transduced B16 cells or B16 tumors. cDNA synthesized from the RNA by reverse transcription (Takara Shuzo, Kyoto, Japan) was amplified at 94°C for 2 min, 30 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 90 s, using primers specific for OX40L or control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts: for OX40L, 5Ј-TGCCAAGAGTGACGTGTCCA-3Ј or 5Ј-GTGGTACTTGGT-TCACAGTG-3Ј; for GAPDH, 5Ј-ATGGTGAAGGTCGGTGTGAACGGA-3Ј or 5Ј-TTACTCCTTGGAGGCCATGTAGGC-3Ј. The PCR products were run on 1% agarose gel and stained with 0.5 g/ml ethidium bromide.
Flow Cytometric Analysis. To assess OX40L expression on transduced B16 cells, cells were stained for 30 min at 4°C with phycoerythrin-conjugated antimouse OX40L monoclonal antibody (mAb; clone RM134L; eBioscience, San Diego, CA) or phycoerythrin-conjugated isotype-matched control antibody (BD Biosciences PharMingen, San Jose, CA). Stained cells were analyzed on an EPICS XL cytometer with EXPO32 ADC software (Beckman Coulter, Miami, FL). To determine the percentage of stained cells above the control staining, 1% of false positive events was accepted in the isotypematched antibody.
Tumor Therapy Models. Tumor cells (3 ϫ 10 5 B16, 5 ϫ 10 5 LLC, 2 ϫ 10 5 Colon-26, or 5 ϫ 10 5 E.G7-OVA) were injected s.c. in the right flank of mice at day 0. When the tumors became palpable (i.e., approximately 4 mm in diameter; day 8 for B16, day 7 for LLC, day 5 for Colon-26, and day 7 for E.G7-OVA), they received injections of 50 l of 10 9 plaque-forming unit (pfu) of AdOX40L or AdNull in PBS or PBS alone. The size of each tumor was measured using calipers every other day, and the tumor volume was calculated as length ϫ width 2 ϫ 0.52. When the mice became moribund or the diameter of the tumors reached 15 mm, they were sacrificed, and this was recorded as the date of death for the survival studies.
Tumor Challenge Model. For immunization, 10 6 B16 cells transduced with AdOX40L or AdNull at a multiplicity of infection of 50 for 3 h or PBS and irradiated (5000 rad) were injected s.c. into the left flank of mice twice at a 1-week interval. Fourteen days after the last immunization, the mice were challenged with s.c. injection of 3 ϫ 10 5 B16 in the right flank. The size of tumors in the right flank was measured as described above.
CTLs. Ten days after the intratumoral injection of adenovirus vectors in the tumor therapy model, or 10 days after the tumor challenge after the immunization in the tumor challenge model, splenocytes were isolated and restimulated at 3 ϫ 10 6 cells/ml with mitomycin C-treated tumor cells (10 6 cells/ml) in 24-well culture plates. After 5 days, viable cells were harvested as effector cells and tested for their ability to lyse target cells using the lactate dehydrogenase cytotoxicity assay kit (Promega, Madison, WI). The percentage of cytotoxicity was calculated as 100 ϫ [(experimental release Ϫ spontaneous release)/(maximal release Ϫ spontaneous release)] (26). Spontaneous or maximal release was obtained from target cells incubated in medium alone or in lysis buffer included in the kit, respectively. Immunohistochemistry. Three days after the intratumoral injection of adenovirus vectors in the tumor therapy model, the tumors were removed, and 5-m-thick frozen sections were prepared and fixed in acetone. After blocking nonspecific staining and endogenous peroxidase, sections were incubated with 0.31 g/ml antimouse CD4 mAb (clone RM4 -5; BD Bioscience PharMingen), 10 g/ml antimouse CD8 mAb (clone KT15; Serotec, Kidlington, United Kingdom), 0.5 g/ml antimouse OX40L mAb (clone RM134L; eBioscience), 10 g/ml antimouse OX40 mAb (clone OX86; Serotec), or 5 g/ml isotypematched rat IgG2a (BD Bioscience PharMingen) overnight at 4°C. After washing, the samples were then incubated with 2.5 g/ml biotinylated rabbit antirat immunoglobulins (DakoCytomation, Glostrup, Denmark) for 15 min at room temperature. Signals were visualized with horseradish peroxidaseconjugated streptavidin and 3,3Ј-diaminobenzidine chromogen/substrate mixture (Nichirei, Tokyo, Japan). The specimens were then incubated with 2.5% methyl green for nuclear counterstaining. Sections were assessed by counting the number of positive cells in 10 randomly selected high-power fields (hpf; magnification, ϫ400). CD4 ؉ T-Cell Responses. E.G7-OVA tumor-bearing C57Bl/6 mice were treated with adenovirus vectors as described in tumor therapy model. Ten days after the intratumoral injection, splenic CD4 ϩ T cells were magnetically isolated using antimouse CD4 magnetic beads (clone L3T4; Miltenyi-Biotec, Auburn, CA). In 96-well plates, 5 ϫ 10 5 CD4 ϩ T cells were then cocultured with 5 ϫ 10 4 irradiated dendritic cells (3000 rad) with or without 50 g/ml OVA. After 4 days, the supernatant was analyzed for the mouse IFN-␥ and interleukin 4 (IL-4) contents by ELISA (BioSource International, Camarillo, CA), and cell proliferation was measured using a WST-1 cell proliferation assay system (Takara Shuzo). The percentage of proliferation was calculated as 100 ϫ [(experimental absorbance) Ϫ (background absorbance)]/[(absorbance at start of the coculture) Ϫ background absorbance].
Statistical Analysis. Statistical comparison was made using the two-tailed Student's t test, and a value of P Ͻ 0.05 was accepted as indicating significance. Survival evaluation was carried out using Kaplan-Meier analysis.
RESULTS

In Vitro and in Vivo Expression of OX40L Mediated by
AdOX40L. AdOX40L-mediated in vitro and in vivo expression of OX40L was confirmed by reverse transcription-PCR and flow cytometric analyses ( Fig. 1; Fig. 2 ). reverse transcription-PCR analysis demonstrated that 0.7-kb fragments corresponding to the OX40L cDNA were amplified with total RNA from AdOX40L-transduced B16 cells, but not with that from AdNull-transduced B16 cells and nontransduced B16 cells (Fig. 1A) . The integrity of the RNA was shown by amplification of GAPDH cDNA in AdOX40L-transduced B16 cells and control cells (Fig. 1A) . Similar results were achieved in transduced B16 tumors in vivo (Fig. 1B) . Reverse transcription-PCR reaction produced 0.7-kb OX40L cDNA fragments in the total RNA sample only from AdOX40L-transduced B16 tumors (Fig. 1B) . Control GAPDH reverse transcription-PCR products were detected in RNA samples from the Ad OX40L-and AdNull-transduced B16 tumors as well as the nontransduced B16 tumors (Fig. 1B) . The in vitro OX40L expression on AdOX40L-tranduced B16 cells was further confirmed by flow cytometric analysis; 79.2% of AdOX40L- A, in vitro expression of OX40L mRNA. B16 cells were transduced with AdOX40L or AdNull (multiplicity of infection 50, 3 h) or PBS (mock transduction), and 48 h later, total cellular RNA was extracted from the transduced cells. B, in vivo expression of OX40L mRNA. Three days after treatment of B16 tumor-bearing C57Bl/6 mice with intratumoral injection of 10 9 pfu of AdOX40L or AdNull or PBS, total cellular RNA was isolated from the treated tumors. For both panels, cDNA generated from the extracted RNA was amplified with the primers for OX40L mRNA (top) or control GAPDH mRNA (bottom). PCR products were resolved in 1% agarose gel and stained with ethidium bromide. (Fig. 2) .
Antitumor Effects of Intratumoral Administration of AdOX40L. Treatment of the well-established tumors with intratumoral injection of AdOX40L induced inhibition of the tumor growth, resulting in improved survival of the treated mice (Fig. 3) . Intratumoral administration of AdOX40L to 8-day established B16 tumors in C57Bl/6 mice (H-2 b ) induced a significant suppression of tumor growth and prolonged survival compared with AdNull or PBS (tumor volume days 9 -15, P Ͻ 0.05; survival, P Ͻ 0.05; Fig. 3A ). The growth of less immunogenic LLC tumors in C57Bl/6 was also restrained significantly by intratumoral administration of AdOX40L, and 40% of treated mice survived for 10 weeks, at which time the experiment was terminated (tumor volume days 13-25, P Ͻ 0.05 to all other groups; survival, P Ͻ 0.05 to all other groups); whereas LLC tumors that received injections of AdNull or PBS grew similarly, and none of the LLC tumor-bearing mice survived (Fig. 3B ). In the Colon-26 tumor model in BALB/c mice (H-2 d ), AdOX40L significantly suppressed the growth of 5-day established Colon-26 tumors and prolonged the survival of the treated mice when injected intratumorally, in contrast with AdNull or PBS (tumor volume days 7-15, P Ͻ 0.05; survival, P Ͻ 0.05; Fig. 3C ). Tumor-Specific CTL Responses Induced by Intratumoral Administration of AdOX40L. Direct administration of AdOX40L to B16 or Colon-26 tumors elicited tumor-specific CTL activity (Fig. 4) . C57Bl/6 mice bearing B16 tumors received injections intratumorally of AdOX40L, AdNull, or PBS (Fig. 4, A and B) . Splenocytes were obtained from the treated mice 10 days after the injection and restimulated by in vitro culture with mitomycin C-treated B16 cells. Effector cells generated from splenocytes of AdOX40L-treated mice exhibited the cytotoxic response against B16 cells, but effector cells from the control groups of mice treated with AdNull or PBS could not lyse B16 target cells (Fig. 4A) . No apparent lysis of irrelevant but syngenic LLC target cells was observed regardless of the treatment, confirming the AdOX40L-induced tumor-specific cytotoxicity against B16 cells (Fig. 4B) . Similar to B16 tumors in C57Bl/6 mice, the intratumoral administration of AdOX40L exhibited Colon-26-specific CTL responses in Colon-26 tumor-bearing BALB/c mice (Fig. 4, C and D) . The cytotoxic response against Colon-26 cells was obtained using splenocytes only from AdOX40L-treated mice (Fig. 4C) . In contrast, no apparent lysis was achieved against irrelevant but syngenic BALB/ 3T3 fibroblasts with any treatments in the Colon-26 tumor-bearing mice (Fig. 4D) . Fig. 5, G-I) ]. Interestingly, increased numbers of OX40-expressing cells were observed only in the AdOX40L-transduced tumors, suggesting that CD4 ϩ T cells and CD8 ϩ T cells infiltrating the AdOX40L-treated tumors described above were activated [OX40 ϩ cells/10 hpf: AdOX40L, 219; AdNull, 17; and PBS, 19 (Fig. 5, J-L) ]. With isotype-matched control IgG, only minimal staining was detected in these tumors treated with AdOX40L, AdNull, or PBS (Fig. 5, M-O) .
Requirements of CD4 ؉ and CD8 ؉ T Cells for AdOX40L-Mediated Antitumor Effects. To delineate the role of CD4 ϩ T cells and CD8 ϩ T cells in the antitumor responses elicited by intratumoral administration of AdOX40L, B16 tumors established in wild-type, CD4
ϩ T cell-deficient (CD4Ϫ/Ϫ), or CD8 ϩ T cell-deficient (CD8Ϫ/Ϫ) C57Bl/6 mice were treated by intratumoral injection with 10 9 pfu of AdOX40L (Fig. 6 ). The growth of B16 tumors in CD4Ϫ/Ϫ and CD8Ϫ/Ϫ mice was not diminished by the AdOX40L treatment compared with that in wild-type mice receiving the identical treatment, and it was similar to the growth of PBS-treated B16 tumors in wild-type mice (days 7-15, P Ͻ 0.05, CD4Ϫ/Ϫ and CD8Ϫ/Ϫ mice compared with AdOX40L-treated wild-type mice; P Ͼ 0.05 or P Ͼ 0.05, CD4Ϫ/Ϫ or CD8Ϫ/Ϫ mice compared with PBS-treated wild-type mice, respectively; Fig. 6 ). As an additional control, PBStreated B16 tumors in CD4Ϫ/Ϫ and CD8Ϫ/Ϫ mice grew progressively as those in wild-type mice (P Ͼ 0.5 or P Ͼ 0.2, CD4Ϫ/Ϫ or CD8Ϫ/Ϫ mice compared with wild-type mice, respectively; not shown).
In Vitro Responses of CD4 ؉ T Cells from AdOX40L-Treated Mice. In vivo AdOX40L-mediated modification of tumors to express OX40L developed tumor-specific CD4 ϩ T cells that proliferated in a tumor antigen-specific manner and predominantly secreted the Th1-associated cytokine IFN-␥ in vitro (Fig. 7) . In this context, C57Bl/6 mice bearing E.G7-OVA tumors expressing OVA as a model tumor antigen were treated with intratumoral injection of AdOX40L, AdNull, or PBS on day 7. Ten days after the treatment, splenic CD4 ϩ T cells were isolated and assayed for their proliferating reactivity to OVA in the presence of syngenic bone marrow-derived dendritic cells as APCs (Fig. 7A) . Although a similar proliferative response to OVA was achieved in each CD4 ϩ T-cell group as compared with the corresponding OVA depletion culture (AdOX40L, 2.6-fold, ϩ T-cell proliferation to OVA in the AdOX40L-treated group was greater than that of any other control group (767% proliferation, P Ͻ 0.005 compared with AdNull or PBS; Fig. 7A ).
The level of IFN-␥ or IL-4 secreted from the CD4 ϩ T cells cultured with OVA was then analyzed to determine which of the Th1 or T helper 2 (Th2) immune responses to the tumor antigen was predominantly induced in the treatment of E.G7-OVA tumor-bearing mice (Fig. 7B) . A significant enhancement of IFN-␥ production from CD4 ϩ T cells was observed with intratumoral injection of AdOX40L compared with AdNull or PBS (P Ͻ 0.005, both comparisons; Fig. 7B ). IL-4 production from CD4 ϩ T cells was also significantly enhanced by the AdOX40L treatment (P Ͻ 0.005, compared with AdNull or PBS alone), but the AdOX40L-enhanced level of IL-4 was only modest as compared with that of IFN-␥ (P Ͻ 0.001; Fig. 7B ).
Antitumor Effect of ex Vivo AdOX40L-Transduced Tumor Cells. To avoid the confounding effects by the in vivo genetic modification of the tumors, we examined whether ex vivo AdOX40L-transduced tumor cells could induce antitumor immunity to suppress the tumor growth in the immunization-challenge experiments (Fig. 8) . In this context, C57Bl/6 mice were immunized with AdOX40L-transduced and irradiated B16 cells twice at a 1-week interval and 2 weeks after the last immunization, challenged s.c. with B16 cells (day 0). The AdOX40L-mediated immunization resulted in a significant slowing of the tumor growth with enhanced survival of the immunized mice, in contrast to the control immunization with AdNull-transduced and mock-transduced B16 cells (tumor volume days 13-17, P Ͻ 0.05; survival, P Ͻ 0.05; Fig. 8A ). The protective effect induced by the AdOX40L immunization has correlated to the tumor-specific CTL responses in vivo primed by AdOX40L-transduced tumor cells (Fig.  8B) . Effector cells were generated from splenocytes of mice immunized and challenged as described above, and assayed for their cytotoxic function against the parental B16 tumor cells. Cells from mice immunized with AdOX40L-transduced B16 cells exhibited a 42.2% lysis of B16 target cells at an effector/target ratio of 100/1, whereas those from mice immunized with AdNull-transduced or mock-transduced B16 cells led to only 2.1% or 0.5% lysis, respectively, at the identical effector/target ratio (Fig. 8B, left part) . As a control for the specificity of the detected B16 lysis, no apparent lysis was observed against irrelevant but syngenic LLC cells regardless of the immunization regimen, and the lysis of control LLC targets was within 5% in all groups (Fig. 8B, right part) .
DISCUSSION
This study is based on the hypothesis that Ad vector-mediated in vivo gene transfer of the coding sequence of OX40L to tumor cells will develop a tumor-specific cellular immune response that can suppress the tumor growth and increase the survival of the tumorbearing host. All of our experimental data support this hypothesis. Intratumoral injection of an adenovirus vector expressing mouse OX40L to three different types of mouse tumors inhibited the growth of the established tumors and prolonged the survival of the treated mice. The direct administration of AdOX40L into established tumors mediated the induction of tumor-specific Th1 and CTL immune responses that are essential for antitumor immunity. Indeed, the anti- ϩ T cell-deficient or CD8 ϩ T cell-deficient condition. One important mechanism by which functional immune systems fail to eliminate tumor cells is a failure of adequate tumor-specific T-cell activation (1, 2) . The induction of potent and long-lasting T-cell responses against antigens requires at least two major signals delivered by APCs (3, 4) . The first signal alone that is brought by a T-cell receptor triggering by peptides bound to MHC class I or class II products is not sufficient to elicit competent T-cell responses against antigens. The second signal that is provided by the engagement of costimulatory receptors by their ligands, together with the first signal, is needed for an effective T-cell response specific for the antigen (3, 4) . The costimulatory receptors expressed on T cells can be divided into two groups: the immunoglobulin superfamily (e.g., CD28) and the tumor-necrosis factor receptor superfamily (4). OX40 is involved in the latter. OX40 is preferentially expressed on CD4
ϩ T cells after the T-cell receptor engagement by peptide antigen in the context of MHC class II, and the OX40 triggering with the ligand, OX40L, enhances the effector T-cell function by augmenting the number of antigen-reactive T cells, up-regulating the production of cytokines, and increasing the life span of effector T cells (7, (11) (12) (13) (14) (15) (16) (17) (18) . Activated T cells expressing OX40 have been found in vivo not only in T-cell zones of spleen or lymph nodes, but also in peripheral inflammatory sites including those of growing tumors (7, 8, 27) . Based on these considerations, we envisioned a scenario in which in vivo genetic modification of tumor cells to express OX40L would costimulate tumor-reactive OX40 ϩ T cells within the tumor through OX40L-OX40 interactions, enabling helper CD4 ϩ T cells to facilitate the tumor-specific cellular immunity associated with CD8 ϩ killer T cells. Consistent with this concept, in vivo genetic modification of tumor cells to express OX40L efficiently induced tumor-relevant CTL immune responses, resulting in a suppression of the tumor growth and prolonged survival of the tumor-bearing mice. Additional evidence for this hypothesis comes from the observations that the antitumor immunity mediated by intratumoral administration of AdOX40L was not generated in a CD4 ϩ T cell-deficient or CD8 ϩ T cell-deficient condition and that CD4 ϩ T cells from tumor-bearing mice treated with intratumoral injection of AdOX40L proliferated in vitro and secreted a Th1 cytokine, IFN-␥, rather than a Th2 cytokine, IL-4, in a tumor antigen-specific manner, suggesting that tumor-specific type 1 immune responses were elicited by the AdOX40L treatment. Moreover, the AdOX40L-augmented CD4 ϩ T-cell in vitro proliferation with a tumor antigen was confirmed by the in vivo observation of a marked intratumoral infiltration of OX40 ϩ and CD4 ϩ T cells in the AdOX40L-injected tumors, indicating that in vivo genetic modification of tumor cells to express OX40L increased the number of tumorreactive CD4 ϩ T cells in the tumor-bearing hosts. With regard to the Th1 versus Th2 immune responses of the OX40-OX40L interactions, early in vitro experiments suggested the preferential involvement of Th2 responses (28) , and this was substantiated by in vivo experiments using murine models of Leishmania major infection in BALB/c mice and allergic lung inflammation (29, 30) . However, recent in vivo studies of OX40-and OX40L-deficient mice have provided greater insight and demonstrated that these animals show reductions in both Th1 and Th2 cytokine responses (7, 11) . Furthermore, studies using experimental disease models such as multiple sclerosis, rheumatoid arthritis, and colitis have demonstrated that in vivo blockade of OX40-OX40L interactions decreases the disease severity by inhibiting the associated inflammatory processes including Th1 cytokine production (31) (32) (33) (34) (35) . Taken together, it appears that OX40 engagement with OX40L participates in both Th1 and Th2 responses, and that the preferential participation of either type 1 or type 2 immune responses is influenced by a variety of associated factors, notably inflammatory and microbial products (4) . The present study has demonstrated that the in vivo adenovirus vector-mediated expression of OX40L in tumor cells led to the priming of CD4 ϩ T cells, which could predominantly produce IFN-␥ in response to the tumor antigen, resulting in tumor-specific CTL generation. The AdOX40L-induced tumor-specific Th1 polarity may be due to the immunological state of the treated hosts (i.e., tumor-bearing), the manner by which OX40 is engaged (i.e., gene transfer of OX40L), or the gene delivery system (i.e., adenovirus vector). In this regard, the cytokine profile of CD4 ϩ T cells from treated mice suggested that Th2 cells also have something to do with the antitumor immunity induced by AdOX40L.
Current knowledge concerning the critical costimulatory role of OX40-OX40L interactions in T-cell immunity has been applied to facilitate antitumor immunity by using agonist reagents to OX40 or forced expression of OX40L in mouse tumor models. Morris et al. (36) and Weinberg et al. (37) showed that an i.p. administration of agonist OX40L:immunoglobulin fusion protein or anti-OX40 antibody after s.c. tumor inoculation resulted in prolonged survival in treated mice compared with untreated controls. Similarly, Kjaergaad et al. (38, 39) and Pan et al. (40) i.p. injected agonist anti-OX40 antibody alone or together with immunostimulatory cytokines (i.e., interleukin 2 or interleukin 12) to tumor-inoculated mice and proved the therapeutic efficacy of these treatments. Differing from such strategies to engage OX40 nonspecifically, one recent study was aimed at triggering OX40 for tumor-specific T-cell immune responses. In this study, Gri et al. (41) demonstrated that, when injected s.c., retrovirally OX40L and GM-CSF double-transduced C26 mouse carcinoma cells mounted CTL responses against C26 cells, with the result that the s.c. vaccination with ex vivo OX40L and GM-CSF double-transduced C26 cells improved the survival of mice bearing C26 lung metastasis. The present study directly expands the concept of OX40 engagement in a tumor-specific manner to an in vivo strategy involving intratumoral injection of a recombinant adenovirus vector to express OX40L alone. Although additional studies will be needed to define the detailed mechanisms whereby in vivo genetic modification of tumor cells with AdOX40L induced tumor-specific cellular immunity (e.g., the role of APCs in developing the immunity), in vivo OX40L transduction using a recombinant adenovirus vector may be a potent tumor immunotherapy.
